The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.

Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Moderna (MRNA – Research Report), with a price ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.

GSK Plc’s experimental mRNA flu vaccine showed a positive immune ... from when they select a flu strain to when they ship their product. It also means that for the Northern Hemisphere, they ...